Results 31 to 40 of about 56,585 (263)

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review

open access: yesHuman Vaccines & Immunotherapeutics, 2023
The objective of this study was to critically review the cost-effectiveness (CE) of the recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was conducted in PubMed, Embase, and Cochrane between January 1, 2017, and February ...
Nikolaos Giannelos, Cheryl Ng, D. Curran
semanticscholar   +1 more source

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer

open access: yesHuman Vaccines & Immunotherapeutics, 2023
Individuals who are immunocompromised (IC) due to therapy or underlying disease are at increased risk of herpes zoster (HZ). This study evaluates the public health impact of recombinant zoster vaccine (RZV) relative to no HZ vaccination for the ...
D. Curran   +8 more
semanticscholar   +1 more source

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

open access: yesOpen Forum Infectious Diseases, 2022
Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high.
A. Strezova   +177 more
semanticscholar   +1 more source

Willingness to vaccinate against herpes zoster in Chinese urban population: a mixed-methods study

open access: yesBMJ Open, 2023
Objective Although the herpes zoster vaccine has been available in mainland China since June 2020, residents’ knowledge of herpes zoster and the herpes zoster vaccine is poor, and vaccination rates are low, especially among the elderly, who are at high ...
Ping He   +8 more
doaj   +1 more source

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

open access: yesClinical Infectious Diseases, 2021
Background This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV) at age ≥50 years in 2 pivotal ...
C. Boutry   +168 more
semanticscholar   +1 more source

Knowledge, attitudes, and practices of the United Arab Emirates population towards Herpes Zoster vaccination: A cross-sectional study

open access: yesHuman Vaccines & Immunotherapeutics, 2022
Herpes Zoster is a viral infection that occurs due to reactivation of the Varicella Zoster virus. A vaccine has been approved for adults aged 50 and above for the prevention of Herpes Zoster and its complications.
Teba Al-Khalidi   +7 more
doaj   +1 more source

Reactivation of Herpes Zoster Keratitis Following Shingrix Vaccine

open access: yesCase Reports in Ophthalmology, 2022
We present a case of herpes zoster keratitis reactivation shortly following the Shingrix vaccine. In our patient, reactivation of herpes zoster keratitis occurred a few weeks following the herpes zoster subunit (HZ/su) vaccine.
Tracy J. Lu, Christopher N. Ta
doaj   +1 more source

Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials

open access: yesPain, 2022
Supplemental Digital Content is Available in the Text. Recombinant zoster vaccine is efficacious in reducing herpes zoster incidence in at-risk populations and seems to decrease pain duration and need for pain medication in breakthrough herpes zoster ...
J. Kim   +8 more
semanticscholar   +1 more source

Effect of Routine Varicella Immunization on the Epidemiology and Immunogenicity of Varicella and Shingles

open access: yesViruses, 2022
Varicella-zoster virus (VZV) causes varicella as a primary infection and remains latent in the ganglia until it becomes reactivated to cause herpes zoster. Individuals with varicella develop adaptive humoral and cell-mediated immunity.
Naruhito Otani   +3 more
doaj   +1 more source

Research Trends and Hotspots on Herpes Zoster: A 10-Year Bibliometric Analysis (2012–2021)

open access: yesFrontiers in Medicine, 2022
PurposeHerpes zoster infection, with its considerable burden to individuals and society, remains a challenge around the world. However, to the knowledge of the authors, little bibliometric quantitative or qualitative analysis has been carried out to ...
Jian Zhang   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy